Strategic Growth and De-risking: Gil Blum’s Buy Rating on Crispr Therapeutics AG

Needham analyst Gil Blum maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $81.00.

Gil Blum has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s strategic positioning and potential for growth. The recent collaboration with Sirius Therapeutics to advance the Factor XI (FXI) siRNA program, SRSD107, is a significant step forward. This partnership is seen as a de-risking move, given the interest from large pharmaceutical companies in FXI, and the program’s durability with bi-annual dosing could set it apart from competitors.
Furthermore, Crispr’s management has indicated that this siRNA program aligns well with their increasing focus on the cardiovascular disease (CVD) space, suggesting a strategic expansion of their pipeline. The financial terms of the deal, including a substantial upfront payment and the potential for additional target options, underscore the commitment to this initiative. SRSD107’s positive results in early trials, showing a high level of FXI reduction in healthy volunteers, add to the confidence in its potential success. These factors collectively support the Buy rating and the $81 target price set by Gil Blum.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.